Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine

NCT02648425 is registered in ClinicalTrials.gov with ASLAN Pharmaceuticals as lead sponsor.

NCT NCT02648425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02648425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine
Lead sponsor
ASLAN Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
August 5, 2014
Completion date
September 15, 2017
Enrollment
31 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor